Acute Decompensated Heart Failure

Historical Context

For centuries, the condition now called acute heart failure was known simply as "dropsy" — a word derived from the Greek for water, describing the grotesque swelling of the limbs and abdomen that marked its victims. Physicians of the 17th and 18th centuries had no concept of the heart as a pump that could fail. They saw dropsy as a disease of humors, of corrupted fluids, and they treated it accordingly: bloodletting, mercurial purgatives, and the deliberate induction of diarrhea, in the belief that fluid expelled from the gut was fluid removed from the tissues. For the patient at the bedside, this approach was almost uniformly fatal in accelerating their decline.

The turning point came in 1785. William Withering, a Birmingham physician, published his landmark account of the foxglove plant — Digitalis purpurea — documenting 163 cases in which digitalis produced dramatic diuresis and relief of dropsy. Withering understood that the drug acted on the kidney, not the heart, and he was partly right: digitalis' diuretic effect in the pre-diuretic era was real, even if its mechanism through myocardial inotropy was not yet understood. For nearly 170 years, digitalis was the only meaningful pharmacologic weapon against heart failure.[1]

The discovery of chlorothiazide in 1957 and furosemide in 1963 changed the landscape entirely. Suddenly, physicians could rapidly mobilize fluid. But this was also when the field began to learn an uncomfortable lesson: removing fluid faster does not always translate into better outcomes. The OPTIME-CHF trial in 2002 showed that intravenous milrinone — a phosphodiesterase inhibitor used to boost cardiac contractility — increased hypotension and arrhythmia without reducing death or hospitalization.[2] RELAX-AHF (2013) showed that serelaxin, a vasodilator that looked promising in phase 2, failed to reduce 180-day cardiovascular mortality.[3] ROSE-AHF (2013) showed that low-dose dopamine and low-dose nesiritide failed to enhance decongestion over placebo.[4]

The DOSE trial in 2011 finally provided what the field needed: rigorous, randomized data on the thing clinicians were actually doing every day — giving loop diuretics.[5] High-dose furosemide (2.5× the oral home dose IV) was more effective at achieving decongestion than low-dose, with no meaningful difference in renal outcomes. The CARRESS-HF trial (2012) then showed that stepped pharmacologic diuresis was superior to ultrafiltration in preserving renal function while achieving equivalent fluid removal.[6] The era of ADHF had been defined less by the discovery of miracle drugs than by the rigorous application of a very old one — and by learning which new ones did not work.

Physiology & Pathophysiology

Heart failure is not a single disease — it is the final common pathway of many different insults to the myocardium. But decompensation — the acute flare that brings a patient to the hospital — is usually not a random event. Something tips the balance. The most common precipitants are dietary indiscretion (sodium excess), medication non-adherence, acute coronary syndrome, uncontrolled hypertension, new or worsened arrhythmia (particularly atrial fibrillation with rapid ventricular response), infection, and pulmonary embolism.[1] In roughly 30% of cases, no clear precipitant can be identified — the disease simply progressed.

The central hemodynamic problem is elevated filling pressure. The heart, whether it has reduced ejection fraction (HFrEF) or preserved ejection fraction (HFpEF), can no longer accept blood at normal pressures. Left ventricular end-diastolic pressure (LVEDP) rises, transmitting backward through the pulmonary veins into the pulmonary capillary bed. When pulmonary capillary wedge pressure exceeds approximately 18–22 mmHg, fluid begins leaking into the pulmonary interstitium — and what begins as interstitial edema progresses to alveolar flooding. The patient cannot breathe.

The Frank-Starling mechanism — the principle that cardiac muscle contracts more forcefully when stretched — is the heart's primary short-term defense against rising filling pressures. Up to a point, more stretch means more output. But this relationship is not linear. The failing heart operates on a depressed Starling curve: for any given filling pressure, it generates less output than a normal heart. And when the curve is sufficiently depressed, further increases in preload yield no additional stroke volume — only more congestion. This is the physiologic trap of advanced heart failure: the body's compensatory mechanism (fluid retention by the kidney, driven by neurohormonal activation) makes congestion worse without improving output.[1]

Neurohormonal activation — the release of angiotensin II, aldosterone, norepinephrine, and ADH — evolved to defend against hemorrhage. Faced with low cardiac output, the brain activates these systems to retain salt and water and constrict peripheral vessels. In acute blood loss, that response saves lives. In heart failure, it is catastrophic: vasoconstriction increases afterload the failing heart cannot overcome, and fluid retention fills an already overwhelmed pulmonary circulation. The result is a vicious cycle of congestion, neurohormonal activation, further myocardial injury, and further congestion — which is precisely why the four pillars of guideline-directed medical therapy (GDMT) target these neurohormonal pathways in the chronic management of HFrEF.

Hemodynamic Profiles

The Forrester classification, developed from invasive hemodynamic data after myocardial infarction, organizes ADHF patients along two axes: perfusion (warm versus cold) and congestion (wet versus dry).[1] Clinical assessment — skin temperature, capillary refill, pulse pressure, orthopnea, JVP — can approximate these profiles at the bedside without a pulmonary artery catheter. Getting this classification right in the first hour changes the entire treatment strategy.

Physical Exam & Diagnostics

The diagnosis of ADHF is fundamentally clinical — made at the bedside, informed by context, and then confirmed by biomarkers and imaging.[1] No single sign is both sensitive and specific. The skill lies in pattern recognition: the patient who sits bolt upright (orthopnea), with distended neck veins (elevated JVP), fine bibasilar crackles that do not clear with coughing, bilateral leg pitting edema, and a third heart sound (S3 gallop) produced by rapid ventricular filling against a stiff, volume-overloaded ventricle.

The differential diagnosis of acute dyspnea is broad. Pneumonia, COPD/asthma exacerbation, pulmonary embolism, and anemia can all present with breathlessness and may coexist with heart failure, particularly in elderly patients. The JVP is among the most powerful discriminators: a clearly elevated JVP in the context of dyspnea strongly favors a cardiac cause. A truly normal JVP makes ADHF much less likely — though patients with isolated left heart failure and acute decompensation may present without elevated JVP early in their course.

Finding	Sensitivity	Specificity	Clinical Pearl
Orthopnea	~50%	~70%	Ask specifically: "How many pillows do you sleep with — has that changed?" A change from baseline is as important as the absolute number.
Paroxysmal nocturnal dyspnea	~41%	~84%	Fluid redistributes supine during sleep; PND awakens the patient 2–3 hours after lying down with severe air hunger.
Elevated JVP (>8 cm H₂O)	~50%	~85%	Most underutilized sign. Hepatojugular reflux adds sensitivity: sustained JVP rise >3 cm with RUQ pressure for 10 seconds.
S3 gallop	~25%	~95%	Low sensitivity but high specificity. Listen with the bell at the apex in left lateral decubitus. Confirms elevated LVEDP when present.
Bibasilar rales	~60%	~60%	Only present when pulmonary edema is acute. Many chronic HF patients with elevated PCWP have compensated lymphatics and clear lungs.
Bilateral pitting leg edema	~65%	~50%	Non-specific alone. Venous insufficiency and hypoalbuminemia cause edema without HF. Bilateral symmetric edema tracking with weight gain is more suggestive.

POCUS

Point-of-care ultrasound (POCUS) in ADHF is not a luxury — it is a tool that provides real-time physiologic information unavailable from any other bedside test. In the time it takes to obtain a chest X-ray and await a radiologist's read, an experienced clinician can characterize volume status, LV function, right heart size, and the presence of pleural effusions. That information changes management in a meaningful proportion of cases.

1. B-lines are not just diagnostic — they are a treatment monitor. Serial lung ultrasound during diuresis allows you to track decongestion in real time. Decreasing B-line count mirrors falling pulmonary capillary wedge pressure. The patient who is not clearing B-lines after 48 hours of diuresis is not adequately decongested, regardless of what the weight scale says.
2. Bilateral B-lines rule in; absence rules out. In a patient presenting with acute dyspnea, the presence of bilateral B-lines in two or more zones bilaterally makes ADHF highly likely. Their absence — with predominant A-lines — makes ADHF unlikely and should redirect the clinical workup toward obstructive lung disease, pulmonary embolism, or other causes. This distinction takes less than 90 seconds at the bedside.[7]
3. The IVC is more useful for ruling out congestion than ruling it in. A clearly collapsing IVC (>50% sniff collapse, diameter <1.7 cm) argues strongly against elevated RA pressure and makes significant volume overload unlikely. A plethoric IVC confirms elevated RA pressure but does not by itself establish the etiology — right heart failure from any cause, including tamponade and PE, can pleth the IVC.[8]
4. RV dilation changes the management plan immediately. If POCUS reveals a dilated RV with septal flattening (the "D-sign" on parasternal short axis), the cardiac output is already being limited by interventricular dependence — the failing RV is pushing the septum leftward and reducing LV filling. Aggressive diuresis in this context can precipitate hemodynamic collapse by further dropping RV preload. These patients need careful volume management, RV-specific optimization, and urgent workup for the etiology of right heart failure.
5. POCUS-guided diuresis is the future of inpatient HF care. An integrated protocol — B-line score and IVC diameter at admission, repeated every 24 hours during diuresis — uses the trajectory of POCUS findings alongside daily weights to guide diuretic dosing decisions.[9] A patient who loses 3 kg but still has 20 B-lines bilaterally is not adequately decongested. A patient who loses 1 kg but now has bilateral A-lines and a collapsing IVC may be excessively diuresed. The ultrasound tells you what the scale cannot.

Labs & Imaging

The initial workup for ADHF serves two simultaneous purposes: confirm the diagnosis and identify the precipitant.[1] An unrecognized ACS triggering decompensation demands an entirely different management priority than dietary indiscretion in a known chronic HF patient. Treat both as live possibilities until the workup excludes one.

BNP and NT-proBNP are the cornerstone biomarkers. BNP (brain natriuretic peptide) is released by ventricular myocytes in response to wall stress — the heart's own distress signal. A BNP <100 pg/mL makes ADHF very unlikely (sensitivity ~90%); BNP >400 pg/mL makes it likely. NT-proBNP (the inactive cleavage product) uses age-adjusted thresholds: <450 pg/mL (age <50), <900 pg/mL (age 50–75), or <1,800 pg/mL (age >75) to rule out ADHF. For discharge, a BNP reduction >30–50% from admission, or an absolute NT-proBNP <1,000 pg/mL, is associated with lower 30-day readmission risk and is a reasonable discharge target.

Basic metabolic panel is not merely a box to check — it provides the physiologic context for diuresis. The serum creatinine establishes baseline renal function and will be rechecked daily. Aggressive diuresis reliably causes some creatinine rise; the critical question is whether it reflects genuine renal injury or the expected hemodynamic consequence of decongestion, which is transient and generally tolerable. Sodium matters: hyponatremia (<130 mEq/L) reflects severe neurohormonal activation and carries significant prognostic weight. Potassium and magnesium must be monitored closely — both fall with loop diuretics, predisposing to ventricular arrhythmias. Liver function tests may reflect hepatic congestion from elevated right-heart filling pressures (congestive hepatopathy, with elevated transaminases and bilirubin mimicking cholestasis).

Chest radiograph remains useful but its sensitivity for pulmonary edema lags behind lung ultrasound by 4–6 hours. Classic findings include cardiomegaly (cardiothoracic ratio >0.5), cephalization of pulmonary vasculature, Kerley B lines (horizontal interstitial lines at the lung bases), perihilar haziness ("bat-wing" pattern in frank alveolar edema), and pleural effusions. The CXR may appear relatively normal in patients with chronic, compensated elevated filling pressures whose lymphatics have adapted over time. Echocardiography — ideally within 24 hours of admission if not recently performed — characterizes LV and RV function, identifies valvular pathology, and estimates filling pressures non-invasively.

Treatment

The treatment of ADHF has been characterized more by the failure of novel agents than by their success. What remains is a framework built on fundamentals: remove fluid, reduce filling pressures, restore perfusion, and initiate or continue the chronic therapies proven to reduce mortality. Do not let the search for novelty distract from disciplined execution of the basics.

Intervention	When & How	Evidence & Key Points
IV Loop Diuretics — DOSE Protocol	All "wet" patients. Give IV furosemide at 2.5× the oral home dose. Bolus q12h preferred over continuous infusion (equivalent efficacy, simpler). If inadequate response at 48h, double the dose or add metolazone 2.5–5 mg PO 30 min prior (sequential nephron blockade).	DOSE trial (Felker, NEJM 2011): high-dose furosemide produced greater symptom relief and weight loss vs. low-dose without worse renal outcomes. Bolus vs. continuous infusion equivalent.[5] Diuretic resistance: add metolazone or consider acetazolamide (ADVOR trial, 2022).
IV Nitroglycerin	Hypertensive ADHF or persistent congestion despite diuresis. Start 5–10 mcg/min, titrate to symptom relief and SBP ≥90 mmHg. Particularly effective in "flash" pulmonary edema due to hypertensive crisis.	Venodilation reduces preload rapidly; arterial dilation at higher doses reduces afterload. Do NOT use if SBP <90 mmHg or significant aortic stenosis. Tolerance develops within 24–48h of continuous use.[1]
Supplemental Oxygen / NIV	Target SpO₂ ≥94%. For respiratory distress with hypoxemia, use CPAP or BiPAP first — reduces preload, improves oxygenation, and may avoid intubation. Do not delay in the severely distressed patient.	Non-invasive positive pressure ventilation reduces need for intubation in acute pulmonary edema. Intubation dramatically worsens prognosis in ADHF — avoid it when NIV can suffice.[1]
Pharmacologic Diuresis vs. Ultrafiltration	For cardiorenal syndrome with diuretic resistance, escalate furosemide dose, add thiazide (metolazone), then consider acetazolamide. Reserve ultrafiltration for truly refractory cases after maximal pharmacologic escalation.	CARRESS-HF (Bart, NEJM 2012): stepped pharmacologic therapy superior to ultrafiltration for preserving renal function at 96h with equivalent fluid removal. Ultrafiltration is not first-line.[6]
Avoid Routine Inotropes	Reserve dobutamine and milrinone for true low-output states (cold-profile) with end-organ hypoperfusion. Do NOT use for decongestion or symptom improvement alone.	OPTIME-CHF (Cuffe, JAMA 2002): IV milrinone in decompensated HF increased hypotension and arrhythmia with no reduction in hospital stay, death, or readmission. Routine inotrope use is harmful.[2]
Avoid Serelaxin and Nesiritide	Neither drug improves clinically meaningful outcomes. Do not use serelaxin. Low-dose nesiritide and dopamine do not improve decongestion over placebo and are not recommended.	RELAX-AHF (Teerlink, Lancet 2013): serelaxin failed to reduce 180-day CV mortality.[3] ROSE-AHF (Chen, JAMA 2013): neither low-dose dopamine nor nesiritide improved urine output or renal function vs. placebo.[4]
Initiate / Continue GDMT Before Discharge	Beta-blockers, ACEi/ARB/ARNI, MRA, and SGLT2 inhibitors should be initiated or resumed before discharge in eligible HFrEF patients. Hold beta-blocker only for frank shock, severe bradycardia, or decompensated bronchospasm.	STRONG-HF (Mebazaa, Lancet 2022): intensive up-titration of all four GDMT pillars during and after hospitalization reduced 180-day HF readmission by 34% (15.2% vs. 23.3%, p=0.003). Trial stopped early for benefit.[10]
Discharge Criteria	Near euvolemia (JVP ≤8 cm, minimal edema, no orthopnea), off IV diuretics, stable on oral diuretic regimen, SpO₂ ≥94% on room air, BNP/NT-proBNP trending down from admission, electrolytes and creatinine stable.	Incomplete decongestion at discharge is the primary driver of 30-day readmission. Discharging a "still wet" patient is a preventable adverse event, not a necessary compromise.[1]

Learn More